Edition: India  
> >

Inivata Collaborates with Genomics England to Assess Samples and Explore Potential of Liquid Biopsy to Improve Cancer Management and Patient Outcomes

GlobeNewswire Friday, 13 October 2017 ()

*Inivata Collaborates with Genomics England to Assess Samples and Explore Potential of Liquid Biopsy to Improve Cancer Management and Patient Outcomes*

Pilot study to test Genomics England samples using Inivata's InVision ^TM platform

Research Triangle Park, NC and Cambridge, UK, October 13, 2017 -- Inivata , a global clinical cancer genomics company utilizing an industry-leading liquid biopsy platform to transform patient care, today announces that it is collaborating with Genomics England to assess the quality of blood plasma samples and explore the potential of liquid biopsy to improve disease management and patient outcomes.

In the first phase of a larger pilot, Inivata will analyse plasma samples donated by participants in Genomics England's 100,000 Genomes Project. As well as determining the suitability of plasma, the study will focus on the use of Inivata's world-leading liquid biopsy technology, InVision, to discover the mutations in the human genome that can lead to or demonstrate the presence of cancer.

These results, and those from the two subsequent phases, will be shared with researchers in the UK and around the world - with the potential to develop less invasive sample collection techniques, more effective monitoring processes and, ultimately, better cancer care.

*Michael Stocum, Chief Executive Officer of Inivata, said,* "As a company with a strong UK heritage, we are delighted to have partnered with the 100,000 Genomes Project - a world-leading initiative which is committed to keeping the UK at the forefront of medical innovation and care. This pilot study will enable us to combine our efforts through the sharing of insights and the assessment of how liquid biopsy technology could ultimately transform cancer care within the NHS, saving lives and money."

- Ends -

*About Inivata*
Inivata is a global clinical cancer genomics company utilizing a proprietary, industry-leading liquid biopsy platform to transform patient care.  Using a simple blood test (liquid biopsy), the analysis of ctDNA is a new lower-cost, less invasive, highly sensitive method for oncologists to diagnose and monitor cancer progression and treatment. The InVision(TM) liquid biopsy platform is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge, combines industry-leading sensitivity with a select multi-gene panel to provide clinically actionable information to clinicians. Inivata has established collaborations with world-leading cancer centers and academic institutions, and is partnering with pharmaceutical and biotechnology companies.  The Company has a CLIA lab in Research Triangle Park, NC and laboratories in Cambridge, UK. For more information, please go to www.inivata.com . Follow us on Twitter @Inivata.

*About the 100,000 Genomes Project*

The project will sequence 100,000 genomes from around 70,000 people. Participants are NHS patients with a rare disease, plus their families, and patients with cancer.

The aim is to create a new genomic medicine service for the NHS - transforming the way people are cared for. Patients may be offered a diagnosis where there wasn't one before. In time, there is the potential of new and more effective treatments.

The project will also enable new medical research. Combining genomic sequence data with medical records is a ground-breaking resource. Researchers will study how best to use genomics in healthcare and how best to interpret the data to help patients. The causes, diagnosis and treatment of disease will also be investigated. We also aim to kick-start a UK genomics industry. This is currently the largest national sequencing project of its kind in the world.

*About Genomics England*

Genomics England is a company owned by the Department of Health and was set up to deliver the 100,000 Genomes Project.  This flagship project will sequence 100,000 whole genomes from NHS patients and their families.

Genomics England has four main aims:

· *to bring benefit to patients*
· *to create an ethical and transparent programme based on consent *
· *to enable new scientific discovery and medical insights*
· *to kickstart the development of a UK genomics industry*

The project is focusing on patients with rare diseases, and their families, as well as patients with common cancers. For more information visit www.genomicsengland.co.uk .

Media Contacts:

Consilium Strategic Communications
Chris Gardner/Laura Thornton/ Rosie Phillips  
+44 (0)20 3709 5700

Karen Chandler-Smith
+44 (0)7900 430235
--------------------This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Inivata via GlobeNewswire

Share on
Share on
Post on 
Share by

You Might Like

Other recent news in Press Releases

Lyon Living Adopts RealPage Property Management SOFTWARE to Consolidate Business Applications and Improve Customer Service7th RISC-V Workshop Showcases Breadth of the RISC-V Ecosystem with More Than 45 SESSIONS Featuring Technology Leaders
This DIWALI, Pay through MobiKwik QR Code and Win GoldAdobe Unveils the Next Generation of CREATIVE CLOUD at MAX 2017
KBRA Comments on Conifer Holdings, Inc.’s Recent Stabilization Actions and Estimated Impact of HURRICANES Harvey and IrmaAmerican Energy Society to Host “The Digital Oilfield” at MINUTE MAID PARK, Houston, Texas
Actress and Activist Kate Del Castillo and Emmy Award-Winning Journalist Jessica MALDONADO “Say it Like it is” on reVolver PodcastsAdvantis Corp. Finalizes Oregon Contract, Accepts BITCOIN From Some New Customers
ChristianCinema.com and for King & Country Share PRICELESS the Movie for Free on FACEBOOK LIVEChef Amy Sins' Apple Flatbread Pizza to be Featured at PMA Food Summit in NEW ORLEANS


Environmentally friendly: newsR is hosted on servers powered solely by renewable energy
© 2017 newsR / One News Page Ltd. All Rights Reserved.  |  About us  |  Disclaimer  |  Terms & Conditions  |  Privacy Policy  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Help  |  Contact us  |  DMCA / Content Removal
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter